Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | PTAFR | P25105 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458409 | 0.85 | ALDH1A1 (0.63) | HTR2APTAFRCYP1A2CYP3A4KDM4E | |
| SCHEMBL7672874 | 0.83 | CHRNA7 (0.57) | HTR2APTAFRCYP1A2CYP3A4HTR1A | |
| SCHEMBL82729 | 0.82 | ALDH1A1 (0.54) | PTAFRCYP1A2CYP3A4ALDH1A1CYP2C9 | |
| SCHEMBL6269623 | 0.81 | KDM4E (0.46) | PTAFRCYP1A2CYP3A4KDM4EALDH1A1 | |
| SCHEMBL6271049 | 0.80 | OPRL1 (0.46) | HTR2APTAFRCYP1A2CYP3A4HTR1A | |
| SCHEMBL3458346 | 0.80 | DRD2 (0.54) | PTAFRDRD3ALDH1A1 | |
| SCHEMBL5557428 | 0.80 | DRD2 (0.48) | PTAFRCYP1A2CYP3A4DRD3CCR3 | |
| SCHEMBL83006 | 0.79 | ACHE (0.57) | PTAFRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3458107 | 0.79 | NAMPT (0.64) | HTR2ACYP3A4KCNH2HTR1ADRD3 | |
| SCHEMBL3458104 | 0.79 | NAMPT (0.64) | HTR2ACYP3A4KCNH2HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4599062-B2 | — | — | 2010-12-15 | — | — | JP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | FLT1, VEGFA, FLT4 | HTR2A 2225/4885PTAFR 47/4885CYP1A2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.